Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You went to law school, as shocking as that might seem.
Think: Statute of Limitations
Hey Hoffy, I got a little distracted, but now I have some time to follow through. You have about 15 aliases. Right!?
On one hand, their undying focus on their own compensation, especially the warrants and options, is kind of heartening that they see future value.
But the issue is always equity and fairness to common non-insider shareholders, and whether NEO compensation is reasonable under the circumstances and consistent with market practice.
I have a feeling this might get ugly.
Did someone say car wash?
Crash, the SEC literally maintains offices at the DTCC headquarters building in Jersey City. The SEC also has specific agreements in place to request access to trade and transaction data from DTCC, almost at will. So much for being self regulated.
Horse, don’t care much for werewolfs and vampires, but always been a big fan of Frankenstein and Igor.
I’m basically at a place where there’s either an approval or CRL within the next couple of months. Yes or no; thumbs up or down; heads or tails; odd finger is it…in other words: it’s a very short period of time before we receive an answer on whether there’s any money to be made in this stock, or not. Management is really a secondary consideration at this stage.
As Igor might say: everyone on this message board is Abby Normal.
Thank you for reminding me.
I still may file….and that would be you. ;)
I believe that’s somewhat in the right direction. They made the calculation a long time ago that the UK was an easier path. That MHRA approval would provide for leverage with the FDA in terms of both patient advocacy in the US and the likelihood a partner BP would come into the frame after approval, who would then “lobby” the FDA.
Then of course begging the question: Why has the company elected to first submit their marketing authorization application in the UK rather than to the FDA?
Crash, are verticals still in play?
This really is next level.
Didn’t realize it’s a social club.
Hope he truly conducts himself as an independent director.
They need to fill the seat for now just for voting purposes.
Could be the opposite.
Sarma looks more like a placeholder until they’re ready to sell the company or reconfigure the board to accommodate a partner(s).
It would be interesting to see a markup to show and compare exactly what was edited from the first complaint. But if the substance of the R&R wasn’t fully addressed per your comments below about the table, then the MTD is still an uphill battle.
Agreed, the overall analysis seems sufficient to move past the MTD, but I thought that the last time as well.
In any event, it’s back to square one and on to square two.
On very quick read, the amended complaint is more analytical and seems to be more straightforward in making their argument, especially in drawing the connection between showing a higher percentage of unexecuted sell orders that preceded buy orders, compared to normal trading.
I know, there aren’t.
Waiting plays into the hands of the defendants, who are otherwise happy enough to drag this case out for years, short of a settlement that make sense for them.
Waiting for new legal precedent when there are no relevant Federal cases that are pending a ruling for a related matter is nonsense as well.
One reason to wait is in the event there are ongoing settlement negotiations. Waiting to make sure there are no typos is nonsense.
No, but I know you ;)
I guess it’s that old trusted legal strategy of winning by losing your MTD.
Saw that on TV once — on that show Law & Order SUV.
Call me crazy, but rather see a higher stock price.
I know, I’m a heretic for even suggesting that.
CM is having a difficult time proving loss causation as evidenced by the fact that the MTD was granted. Can’t imagine how difficult it will be to prove intent (albeit not absolutely required, but still important) and spoofing per the letter of the law when all the other more nuanced factors come into play, including the highly technical aspects of HFT.
Wasn’t it Posner who commented that this complaint is testing new case law, or something along those lines?
I’ve advocated for a settlement from the beginning, since the utility to shareholders was greatest last year, which will diminishes over time. Even a modest settlement last year may have fully funded the company for a year and to led nearly no dilution that would have stabilized the stock price.
Now that presupposes any of the marker makers would be willing to settle early in the lawsuit. Maybe they’re just happy to play this out for as long as possible? But this litigation is very expensive, involving over 30 or more highly paid attorneys (hourly rates > $1,000) from like 6 or 7 different law firms.
This of course begs the question: where are all the derivative lawsuits against these market makers if the spoofing case is so strong? In any event, amending and re-filing the complaint puts everyone back to square one.
From the perspective of NWBO shareholders and valuation of our investment, this is a non-factor. Maybe from a market integrity perspective, this case could be important. But still years from getting to that point, if ever.
FT is probably the best business oriented newspaper in the world. Much better than the WSJ, which has gone way down hill for obvious reasons.
Liked the article, and fairly consistent with points made here. The root cause isn’t spoofing per se, it’s the high frequency trading that’s largely unregulated. HFT is trading in ways that are impossible for humans to execute on their own, and the regs just haven’t caught up with what’s rules govern the algorithms.
Not obvious to me that NWBO will be able to overcome the deficiencies that led to the granting of the MTD in the first place. But it’s more or less a side show anyway, since by the time it takes this case to progress to a point where there might be a settlement, all the milestones (i.e., RA submissions, approvals, uplisting, partnerships, etc.,) that impact the business will be already determined, one way or another.
When issues arise over weaknesses in internal controls, it’s not unusual for the general counsel to sign the SEC disclosure. I believe the thought is that under the circumstance you don’t want the same person responsible for the internal control weakness (i.e., the CFO) being the same person certifying the accuracy and completeness of the disclosure.
I chased him down, but my net was too small.
The song is about a bad breakup with Beatty Crocker.
Yes, the Gorky Park Bench. Not to be confused with the MacArthur Park Bench where someone left their cake out in rain.
I know one sleeper cell in Moscow goes by the code name NWBO Stock Price,
He is Board Certified oncologist. Say what you want about me, but Alpha deserves some respect regardless of whether someone agrees or disagree with his views. His day is spent treating cancer patient. Let that sink in.
Look, Alph, I’m a business professional and you’re an oncologist. My investment in NWBO from a professional perspective is the same as if you decided to live on a study diet of bacon burghers washed down with a daily glass of red dye #2. We both know better.
Having said that, keep the faith — I do believe this will work out. Maybe not at the level we had hoped given the length of time we’ve invested, but at least at some meaningful return. The hour glass is now turned with the submission, so something has to happen by summer, one way or the other.
I’ve made this point many times over the years: the biggest problem for shareholders is that the stock is traded as an OTC. That limits institutional investment. I could list ten other reasons why it only takes loose change to buy a share of NWBO. But I’ll demure.
It’s very uncommon for an OTC stock not listed on an another major foreign exchange to have market caps exceeding $ billion — NWBO’s market cap is actually very good for an OTC stock, but the dilution doesn’t allow that to be reflected in the stock price. Note: The Frankfurt exchanged that NWBO is listed is the German version of their OTC.
Let’s also be clear, the MTD for the spoofing case has been granted for the time being. Not clear the case will survive at all.
It’s a minefield on this message board.
Anytime an insider sells shares it always raises questions. The one silver lining is that he couldn’t sell on any insider information that was materially negative. My guess is there was no certain news at the time of the sale. And we don’t know his own personal financial situation or strategy to speculate on his motive as to why he didn’t use other resources to pay his taxes.
When it comes to insider sales, typically you want to consider how often and how many insiders. One insider one time is not terribly alarming. NVCR on the other hand had multiple insiders selling multiple times — everyone should have known where that was headed.
One of the very few times I agree with you, even going back to your private message boards.
The difficulty and risk with franchising a process is quality control and malpractice exposure, not to mention all the manufacturing licenses required and trained technicians that need to be hired and dispersed presumably around the globe. And for at least the present, this is just an orphan indication, so there’s no economies of scale that a franchise can benefit.
Another positive take away from the emailed letter w/ the PR attached that Innis sent me this morning is that I doubt the company would engage in negotiations with a vendor for an equipment manufacturing contract unless they were more or less confident with approval. Although, there are likely contingencies built into a pending contract in the event that everything doesn’t go according to plan.
Thanks. Thought it was a bit odd that Innis would just send to me, or perhaps just some of the larger shareholders?
See, that’s such a dead give away that your Hoffy.
Cut and paste at will on Twitter…hahahah!!!
I credit my cut and paste skills to you, Sensei.
Was busy reading the nice email that Innis sent to my inbox. Did he just send it to me or did he copy all message board posters?
Hahaha.
Right. You’re the best cut and paste legal beagle (beagle, not eagle) of all time.
Might I suggest another alias for you: “Cut’n_Paste.”